Arnatar Therapeutics has officially emerged from stealth.

With a $52M Series A led by Eight Roads & 3E Bioventures and ‪@fda.gov‬ #OrphanDrug + #RarePediatricDisease designations for ART4 in #AlagilleSyndrome, we’re advancing a new era of #RNABasedTherapies.‬

Learn more: https://bit.ly/4m39ec1

PIF Partners' Investigational Therapy Receives Rare Pediatric Disease Designation from FDA PIF Partners has reached a significant milestone with the U.S.

www.linkedin.com/pulse/pif-pa...

PIF Partners' Investigational Therapy Receives Rare Pediatric Disease Designation from FDA

kstrategyand.com/pharma-news

#PIFPartners #FDAApproval #RarePediatricDisease #SystemicJuvenileIdiopathicArthritis #ClinicalTrials #Humanteconomy #Humantech #KStrategyand